← FDA DRUG APPROVALS

FDA NDA · NDA216227

IHEEZO

chloroprocaine hydrochloride ophthalmic gel

Sponsor: HARROW EYE

APPLICATION
NDA216227
TYPE
NDA
ORIGINAL APPROVAL
2022-09-27
LATEST ACTION
2022-09-27
ROUTE
OPHTHALMIC
DOSAGE FORM
GEL
MARKETING STATUS
Prescription

Products

IHEEZO · ReferencePrescription
CHLOROPROCAINE HYDROCHLORIDE 3% · GEL · OPHTHALMIC

Approval history

2022-09-27Type 3 - New Dosage Form · Original · standardLetterAP
VIEW ON DRUGS@FDA ↗

Related on SPEQ

Pharma industryGMP disciplineFDA drug shortagesFDA enforcement & recalls

Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.

Weekly Briefing

Get the Weekly GxP Briefing

Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.

Read a past issue →